Abstract
The prognosis of non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE) due to pleural carcinomatosis is said to be poor. Several reports discussed that the anti-VEGF antibody had the effect of decreasing vascular permeability and reducing pleural effusion. Ramucirumab (RAM), a VEGFR-2 antibody that inhibits tumor angiogenesis, is widely used with docetaxel (DTX) after failure of platinum doublet chemotherapy. Presently, there is no data concerning the tolerable safety profile and efficacy of administering RAM+DTX to patients with NSCLC with MPE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
